Gynecomastia
Gynecomastia is enlargement of male breast tissue from glandular proliferation, driven by estrogen acting relative to androgen rather than by absolute estrogen levels alone.[1] Low thyroid function and elevated prolactin add to the estrogenic load that produces it.
| Gynecomastia | |
|---|---|
| Synonyms | Male breast enlargement |
| Classification | Endocrine |
| Metabolic driver | Estrogen acting relative to androgen, with prolactin and low thyroid adding to it |
| Standard treatment | Remove the cause (drugs, hormone excess); DHT studied in persistent pubertal cases |
| Ray's verdict | A sign of estrogen excess relative to androgen |
Mechanism
[edit]Testosterone converts partly to estradiol outside the testes, through aromatization of adrenal and testicular androgens, and this extraglandular estradiol is what produces feminization "commonly manifested by gynecomastia" when estrogen is relatively or absolutely in excess.[1] Dihydrotestosterone (DHT) blocks these effects directly at the estrogen receptor rather than through the androgen receptor, competing with estradiol for the same binding site; the study that established this proposed DHT as the main protective antiandrogen against gynecomastia in men.[1]
Serum estradiol correlates poorly with this whole-body estrogenic load. Gynecomastia, like central obesity and muscle atrophy, is commonly seen in men with unremarkable serum estradiol but high whole-body estrogenic tone, since almost any stressed or inflamed tissue can produce estrogen locally, and prolactin tracks that whole-body estrogenic tone more reliably than serum estradiol does.[2]
Men with gynecomastia carry more estrogen, cortisol-type hormones and pituitary gonadotropins in their blood, and fewer androgens, than healthy men.[3] Breast enlargement and slow beard growth also turned up in young men before an early heart attack, alongside higher estradiol and estrone and normal testosterone.[4]
Aromatase can produce estrogen in fat cells, fibroblasts, smooth muscle cells, breast and uterine tissue, pancreas, liver, brain, bone, skin, etc. Its action in breast cancer, endometriosis, uterine cancer, lupus, gynecomastia, and many other diseases is especially important.
— Ray Peat[5]
Gynecomastia is among the effects seen with growth hormone (GH) treatment, alongside carpal tunnel syndrome, myalgia, and tumor growth. GH overlaps closely in function with prolactin.[6]
Breast growth in beer drinkers may come from estrogen made by the yeast itself rather than from the hops.
Yeast can produce estradiol, so they think that the yeast for men is a major source of the breast development in beer drinkers.
— Ray Peat[7]
Drug-induced gynecomastia
[edit]5-alpha-reductase inhibitors (finasteride, dutasteride) lower DHT while leaving estrogen unchanged, shifting the balance toward estrogen; case reports document gynecomastia from topical as well as oral finasteride.[8] Antiandrogen therapy for prostate cancer (bicalutamide and newer androgen receptor pathway inhibitors) produces gynecomastia at a markedly higher rate than androgen-deprivation therapy alone; a 2025 meta-analysis of 18 randomized trials (5,036 patients) found androgen-receptor-pathway-inhibitor monotherapy raised gynecomastia risk about fivefold versus androgen-deprivation therapy alone, and prophylactic tamoxifen significantly reduced the incidence of gynecomastia and breast pain from bicalutamide monotherapy.[9]
Standard treatment
[edit]Intramuscular dihydrotestosterone heptanoate (DHT-hp), 200 to 400 mg every 2 to 4 weeks for 16 weeks, reduced breast size 67% to 78% in adolescent boys with persistent pubertal gynecomastia, with no regrowth seen up to 15 months after treatment; serum DHT rose to a mean of 278 ng/dL by week 16 while testosterone and estradiol fell.[10]
Practice
[edit]Check drugs (especially 5-alpha-reductase inhibitors and antiandrogens), thyroid function, and estrogen load. Get medical evaluation for any breast mass, since true glandular gynecomastia needs to be distinguished from simple fat accumulation.
See also
[edit]References
[edit]- ↑ 1.0 1.1 1.2 Casey RW, Wilson JD. Antiestrogenic action of dihydrotestosterone in mouse breast: competition with estradiol for binding to the estrogen receptor. J Clin Invest. 1984;74(6):2272-8.
- ↑ Nikkari T, Valavaara M. Effects of androgens and prolactin on the rate of production and composition of sebum in hypophysectomized female rats. J Endocrinol. 1970;48(3):373-8.
- ↑ Tarutinov VI, Maevskaia LP, Fedorova LV, Pershko NIu, Topchiĭ VB. "Functional state of the hypophysis, adrenal cortex and gonads in patients with gynecomastia". Vopr Onkol. 1991;37(5):576-579. PMID 1837392. In Russian; abstract reports higher blood estrogens, glucocorticoids and pituitary (mainly gonadotropic) hormones with lower androgens.
- ↑ Phillips GB. "Evidence for hyperoestrogenaemia as a risk factor for myocardial infarction in men". Lancet. 1976;2(7975):14-18. doi:10.1016/s0140-6736(76)92968-8. PMID 59076. 15 men with a heart attack at age 32-42 vs 15 age-matched healthy men; estradiol 43.5 vs 33.5 pg/mL, estrone 50.7 vs 37.5 pg/mL; testosterone and DHT not different; 3 of 15 had gynecomastia and 7 of 15 strikingly slow beard growth, which appeared to precede the infarction.
- ↑ Tissue-bound estrogen in aging, Ray Peat
- ↑ Peat R. Growth hormone: Hormone of Stress, Aging, & Death?
- ↑ Ask the Herb Doctor: Endocrinology (Part 3), KMUD, 2017-05-19
- ↑ Thomas M, Sinclair R. Painful bilateral gynaecomastia secondary to topical finasteride. Australas J Dermatol. 2025;66(1):40-41.
- ↑ Tsuboi I, et al. Incidence, Management, and Prevention of Gynecomastia and Breast Pain in Patients with Prostate Cancer Undergoing Antiandrogen Therapy: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Open Sci. 2025;73:31-42. Meta-analysis of 18 RCTs; ARPI monotherapy vs ADT 5.19-fold (95% CI 3.58–7.51).
- ↑ Eberle AJ, Sparrow JT, Keenan BS. Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate. J Pediatr. 1986;108(5):851-855.